Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update

Rhea-AI Summary

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will release its financial results for the year ended December 31, 2021, on March 1, 2022. This announcement follows the closing of U.S. financial markets. A conference call and live audio webcast will take place on the same day at 4:30 PM Eastern Time to discuss these results and provide a corporate update. The company focuses on developing therapies for neurological disorders, particularly epilepsy. Investors can access more details on their website for further updates and replay options.

Positive

• Commitment to developing innovative therapies for neurological disorders.
• Focus on addressing high unmet medical needs in epilepsy.

Negative

• None.

BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update after the close of U.S. financial markets on Tuesday, March 1, 2022.

Conference Call/Webcast Information:

Xenon will host a conference call and live audio webcast on Tuesday, March 1, 2022 at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the year-end results and to provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 7079889.

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

 

FAQ

When will Xenon Pharmaceuticals announce its financial results for 2021?

Xenon Pharmaceuticals will announce its financial results for the year ended December 31, 2021, on March 1, 2022.

What time is the Xenon Pharmaceuticals conference call on March 1, 2022?

The conference call for Xenon Pharmaceuticals is scheduled for 4:30 PM Eastern Time on March 1, 2022.

How can I access the Xenon Pharmaceuticals conference call webcast?

The webcast for the conference call can be accessed on the Investors section of the Xenon Pharmaceuticals website.

What is the main focus of Xenon Pharmaceuticals?

Xenon Pharmaceuticals is focused on developing therapies for neurological disorders, with a special emphasis on epilepsy.